BERLIN, May 1, 2009 (GLOBE NEWSWIRE) -- Jerini AG has reached an agreement to sell its wholly owned subsidiary, JPT Peptide Technologies GmbH, to TheraCode GmbH, Mainz, a wholly owned subsidiary of BioNTech AG, Mainz. Under the terms of the agreement, TheraCode GmbH will pay Jerini AG a purchase price of approximately (Eur) 5 million in cash. The sale of JPT Peptide Technologies GmbH to TheraCode GmbH is a further achievement in the implementation of Jerini AG's strategic decision published on October 10, 2008 to divest all non-strategic businesses and to focus on the core business Firazyr.
ISIN: DE0006787476 WKN: 678 747 Regulated Market / Prime Standard; Frankfurt Stock Exchange, Germany Registered Office: Berlin, Germany